Celldex Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Celldex Therapeutics has a total shareholder equity of $785.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $823.2M and $37.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$756.00m |
| Equity | US$785.91m |
| Total liabilities | US$37.27m |
| Total assets | US$823.18m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: TCE2's short term assets ($778.8M) exceed its short term liabilities ($32.1M).
Long Term Liabilities: TCE2's short term assets ($778.8M) exceed its long term liabilities ($5.2M).
Debt to Equity History and Analysis
Debt Level: TCE2 is debt free.
Reducing Debt: TCE2 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TCE2 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: TCE2 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 17.5% each year